Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

New antibody strategy shows promise for halting cyst growth in polycystic kidney disease

Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their function, often leading to dialysis in advanced cases.

18 Nov 2025

Preparing for the respiratory virus season: A guide for families

As respiratory virus season begins, pediatric experts are preparing for an expected rise in cases of Respiratory Syncytial Virus (RSV), which can cause cold-like symptoms in most people but serious illness in infants and older adults.

17 Nov 2025

AI and protein language models can accelerate the design of antiviral antibodies

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study led by researchers at Vanderbilt University Medical Center.

5 Nov 2025

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome.

5 Nov 2025

Northwestern team develops antibody to expose hidden pancreatic cancer cells

Pancreatic cancer is notoriously hard to treat and often resists the most advanced immunotherapies. Northwestern Medicine scientists have uncovered a novel explanation for that resistance: Pancreatic tumors use a sugar-based disguise to hide from the immune system.

3 Nov 2025

COVID-19, RSV, and flu vaccines remain safe and effective

The systematic review provides crucial insights into the efficacy and safety of respiratory virus vaccines, supporting evidence-based immunization practices.

3 Nov 2025

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Congenital heart block, sometimes referred to as cardiac neonatal lupus, is a rare but potentially life-threatening condition that affects babies born to mothers with specific autoantibodies - called anti-SSA/Ro antibodies - which can attack the fetal heart via its electrical conduction system, leading to a slower heart rate.

22 Oct 2025

Logical Biological and Bcell Design announce strategic partnership for engineered disease state materials

Logical Biological, biospecimen and critical raw material leader, and Bcell Design, pioneers in transgenic monoclonal antibody technology, today announced a long term strategic partnership to deliver engineered disease state materials for diagnostic and research markets.

From Logical Biological 7 Oct 2025

FDA grants approval to begin Phase I clinical trials of heart tissue regeneration drug AD-NP1

The body's tissues can get injured in many ways, but while some injuries heal perfectly, others don't heal at all. A cut in the skin, for example, usually heals all on its own, while internal organs, such as the heart after a heart attack or the kidney after an acute injury, remain damaged, leading to diminished function.

6 Oct 2025

Yale researchers develop new test for early leptospirosis detection

In a new study, Yale School of Medicine (YSM) researchers unveiled a novel diagnostic method for detecting leptospiral virulence-modifying (VM) proteins in the blood and urine of hamsters, an advance that could pave the way for early diagnosis of the tropical disease leptospirosis in humans and improved treatment options.

29 Sep 2025

Nirsevimab sharply cuts RSV hospitalizations in U.S. infants during the 2024–2025 season

In a nationwide EHR cohort of over 400,000 U.S. infants during the 2024–2025 RSV season, nirsevimab use was linked to a 77% lower risk of RSV-related hospitalization. The study also found reduced ICU admissions and intubations, supporting broad seasonal protection in routine care.

28 Sep 2025

Researchers develop tool to predict how patients will respond to common multiple sclerosis drug

Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will respond to natalizumab, one of the most commonly used drugs for treating multiple sclerosis.

25 Sep 2025

Scientists outline how future therapies could change type 1 diabetes care

Researchers writing in The Lancet review breakthroughs in type 1 diabetes treatment, from immunotherapies that delay onset to stem-cell β-cell replacement and automated insulin delivery. They stress that equitable access, validated surrogate endpoints, and scalable technologies are crucial for lasting impact.

24 Sep 2025

NIH awards $3.4 million to support research on Crimean-Congo hemorrhagic fever virus

Crimean-Congo hemorrhagic fever virus, or CCHFV, is a biosafety level 4 pathogen and a Category A bioterrorism agent, causing severe viral hemorrhagic fever with mortality rates reaching up to 40%.

24 Sep 2025

Ocrelizumab provides superior control of multiple sclerosis relapses compared to other therapies

New research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) demonstrates that ocrelizumab provides superior control of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.

23 Sep 2025

New microfluidic-based biosensing platform helps track live antibody secretion dynamics

A research team at the Terasaki Institute, led by Dr. Vadim Jucaud in collaboration with Dr. Jing Yong Ye from the University of Texas San Antonio, has developed a new microfluidic-based biosensing platform that allows monitoring cellular secretion of monoclonal antibody in real time.

23 Sep 2025

Experts call for coordinated global action to make the most of Alzheimer’s treatments

The approval of new antibody medications for Alzheimer's disease – lecanemab and donanemab – and diagnostic tests in the blood mark the beginning of a new era in Alzheimer's disease diagnosis and treatment.

23 Sep 2025

Novel method accurately identifies therapeutic antibodies to treat infectious diseases

Scientists at Scripps Research have developed a novel method that uses artificial intelligence (AI) and advanced imaging techniques to more accurately and efficiently identify therapeutic antibodies to treat infectious diseases.

10 Sep 2025

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan’s Drug Regulatory Authority of Pakistan (DRAP).

From BioDlink 8 Sep 2025

Single antibody causes a rare but dangerous reaction to widely-used blood thinner

Researchers at McMaster University have discovered that a rare but dangerous reaction to a widely used blood thinner is caused by a single antibody – overturning decades of medical misunderstanding and opening the door to more precise ways of diagnosing and treating this medical complication.

3 Sep 2025

Monoclonal Antibody News and Research

Further Reading

New antibody strategy shows promise for halting cyst growth in polycystic kidney disease

Preparing for the respiratory virus season: A guide for families

AI and protein language models can accelerate the design of antiviral antibodies

Rituximab shows remarkable success in adults with relapsing nephrotic syndrome

Northwestern team develops antibody to expose hidden pancreatic cancer cells

COVID-19, RSV, and flu vaccines remain safe and effective

Rozanolixizumab prevents congenital heart block in high-risk pregnancy

Logical Biological and Bcell Design announce strategic partnership for engineered disease state materials

FDA grants approval to begin Phase I clinical trials of heart tissue regeneration drug AD-NP1

Yale researchers develop new test for early leptospirosis detection

Nirsevimab sharply cuts RSV hospitalizations in U.S. infants during the 2024–2025 season

Researchers develop tool to predict how patients will respond to common multiple sclerosis drug

Scientists outline how future therapies could change type 1 diabetes care

NIH awards $3.4 million to support research on Crimean-Congo hemorrhagic fever virus

Ocrelizumab provides superior control of multiple sclerosis relapses compared to other therapies

New microfluidic-based biosensing platform helps track live antibody secretion dynamics

Experts call for coordinated global action to make the most of Alzheimer’s treatments

Novel method accurately identifies therapeutic antibodies to treat infectious diseases

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

Single antibody causes a rare but dangerous reaction to widely-used blood thinner

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®